Infants diagnosed with certain risk conditions at ≤12 months of age are recommended to receive 13vPCV and 23vPPV
In addition to the 3 doses of 13vPCV routinely recommended for healthy non-Indigenous children <5 years of age, children ≤12 months of age with risk conditions for pneumococcal disease (see List. Risk conditions for pneumococcal disease) are recommended to receive:
- An additional dose of 13vPCV at 6 months of age
- a dose of 23vPPV at 4 years of age
- a 2nd dose of 23vPPV at least 5 years after the 1st dose of 23vPPV
This is because of the higher disease burden and the possibility of lower antibody responses in these children.2-4
Aboriginal and Torres Strait Islander children diagnosed with risk conditions at ≤12 months of age who live in the Northern Territory, Queensland, South Australia and Western Australia already receive these extra doses as part of their routine schedule.
Any child aged 6 to 11 months with a newly identified risk condition who has not received an additional dose of 13vPCV at 6 months of age should receive this dose at diagnosis. The exception is children who have received a haematopoietic stem cell transplant — these children are recommended to receive 3 doses of 13vPCV after transplantation. See Table. Recommendations for revaccination after haematopoietic stem cell transplant in children and adults.
See Catch-up vaccination for more details, including minimum intervals between doses.
- 13-valent pneumococcal conjugate vaccine
- 23-valent pneumococcal polysaccharide vaccine
Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/recommendations/infants-diagnosed-with-certain-risk-conditions-at-12-months-of-age-are-recommended.